Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Van Braeckel

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Journal of Fungi (Basel, Switzerland)|July 3, 2020
CPAnet Registry-An International Chronic Pulmonary Aspergillosis RegistryChristian B Laursen, Jesper Rømhild Davidsen, Lander Van Acker, et al.
Vaccine|February 27, 2021
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety dataFlor M Munoz, Jakob P Cramer, Cornelia L Dekker, et al.
ERJ Open Research|January 16, 2024
<i>Mycobacterium avium</i> complex pulmonary disease patients with limited treatment optionsStefano Aliberti, Francesco Blasi, Pierre-Régis Burgel, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 7, 2019
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trialsScott C Bell, Peter J Barry, Kris De Boeck, et al.
The Lancet. Respiratory Medicine|December 23, 2021
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trialSivagurunathan Sutharsan, Edward F McKone, Damian G Downey, et al.
Trials|November 20, 2020
Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trialJozefien Declercq, Cedric Bosteels, Karel Van Damme, et al.
Frontiers in Immunology|December 17, 2020
Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19Karel F A Van Damme, Simon Tavernier, Nele Van Roy, et al.
The Journal of Experimental Medicine|March 3, 2025
Replication stress, microcephalic primordial dwarfism, and compromised immunity in ATRIP deficient patientsEvi Duthoo, Elien Beyls, Lynn Backers, et al.
Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.
Science Translational Medicine|August 23, 2023
A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19Karel F A Van Damme, Levi Hoste, Jozefien Declercq, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Journal of Fungi (Basel, Switzerland)|July 3, 2020
CPAnet Registry-An International Chronic Pulmonary Aspergillosis RegistryChristian B Laursen, Jesper Rømhild Davidsen, Lander Van Acker, et al.
Vaccine|February 27, 2021
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety dataFlor M Munoz, Jakob P Cramer, Cornelia L Dekker, et al.
ERJ Open Research|January 16, 2024
<i>Mycobacterium avium</i> complex pulmonary disease patients with limited treatment optionsStefano Aliberti, Francesco Blasi, Pierre-Régis Burgel, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 7, 2019
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trialsScott C Bell, Peter J Barry, Kris De Boeck, et al.
The Lancet. Respiratory Medicine|December 23, 2021
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trialSivagurunathan Sutharsan, Edward F McKone, Damian G Downey, et al.
Trials|November 20, 2020
Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): A structured summary of a study protocol for a randomised controlled trialJozefien Declercq, Cedric Bosteels, Karel Van Damme, et al.
Frontiers in Immunology|December 17, 2020
Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19Karel F A Van Damme, Simon Tavernier, Nele Van Roy, et al.
The Journal of Experimental Medicine|March 3, 2025
Replication stress, microcephalic primordial dwarfism, and compromised immunity in ATRIP deficient patientsEvi Duthoo, Elien Beyls, Lynn Backers, et al.
Lancet (London, England)|November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialHarry G M Heijerman, Edward F McKone, Damian G Downey, et al.
Science Translational Medicine|August 23, 2023
A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19Karel F A Van Damme, Levi Hoste, Jozefien Declercq, et al.
Pageof 8